ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

NCI Drug Development Program Produced 7 Drugs In 10 Years, Chabner Tells Group

February 3, 1995

New NCI division For Center, Training, Organ Systems, Construction Seen As Likely Prospect

April 17, 1987

In Brief: Oncology Nurse Rumored For NCAB; Rosenberg To Give Karofsky Lecture; Fundraiser’s $$ Short

December 14, 1990

Garfinkel to Retire From ACS; Health to Succeed Him

July 20, 1990

Budget Year

November 12, 2010

(8-page issue)

October 4, 2002